Diagnosis and Treatment of Patients With Cystic Fibrosis

StatusTerminated
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 300 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Trial status: Active, Not Recruiting to Terminated Sponsor's reason: PI left NIH
    • Primary and study completion dates: Jan 30, 2026
    v300
  2. 12 versions Re-verified since Aug 14, 2025, no change to tracked fieldsv288-v299
  3. Enrollment target: estimated 9999 to confirmed 79
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v287
  4. 36 versions Re-verified since Jul 17, 2024, no change to tracked fieldsv251-v286
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is an omnibus protocol for studying patients with cystic fibrosis. The main purpose of the study is to obtain samples and data collected during standard clinical care for future research to expand knowledge of the natural history, clinical manifestations (phenotypes) and the genetic variants (genotypes) of cystic fibrosis.
Trial Details
NCT Number NCT00001223
Lead Sponsor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
(from sponsor)		 Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes, Pancreatic Insufficiency (Exocrine and Endocrine)
Related terms Bronchiectasis, Congenital Abnormalities, Cystic Fibrosis, Diabetes Mellitus, Exocrine Pancreatic Insufficiency, Liver Diseases
Enrollment 79 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov